Advisory Board

Our advisory board is comprised of respected health care officials and doctors with extensive backgrounds.

Craig S. Hill, Ph.D.

Industrial Medical Diagnostics
Dr. Craig Hill has been involved in the industrial medical diagnostics field for nearly 30 years working in research, product development, and scientific/clinical affairs. Craig received his B.S. degree in Biochemistry from U.C. Berkeley and his Ph.D. in Cell and Molecular Biology from the University of Wisconsin, Madison followed by three years of post-doctoral work at the Max-Planck Institute in Germany. Craig managed clinical diagnostic assay research and development at Hybritech Inc. and the Nichols Institute. This was followed by 20 years at Gen-Probe Inc. working in molecular infectious disease diagnostics with external scientific collaborators on clinical trials and scientific publication/presentation programs.

John Gu, Ph.D.

President & Chief Science Officer of Renascions
Dr. John Gu has over 14 years experience in scientific research and product development. Trained in bioinorganic chemistry (PhD), he pioneered human SNP research and applications as an NIH extramural fellow in the Human Genome Project. He has led development of innovative commercial diagnostic products, including CodeLink P450 SNP Bioarray, and HepaType, AsthmaType, and IressaType in vitro diagnostics. Dr. Gu managed pre clinical and Phase I/II development of natural human interferon, and served as faculty member and program director at Sidney Kimmel Cancer Center.

Howard C. Birndorf

Co-founder and director of IDEC Pharmaceuticals Corporation
Mr. Birndorf was founder, chairman and CEO of Nanogen from 1993 until 2009. Mr. Birndorf was a co-founder and Chairman Emeritus of Ligand Pharmaceuticals Incorporated, where from January 1988 to November 1991 he was President and Chief Executive Officer. He was also a co-founder, director and Executive Vice President of Gen-Probe Incorporated, co-founder and Vice President of Corporate Development at Hybritech Incorporated, co-founder and director of IDEC Pharmaceuticals Corporation, and was involved in the formation of Gensia Pharmaceuticals, Inc. (currently known as SICOR Inc.) where he was a director. From November 1991 to January 1993, Mr. Birndorf was President of Birndorf Technology Development, an investment and consulting company, and a founding director of Neurocrine Biosciences, Inc. He is a founder and Chairman of Cascade Bioscience. He received the Life Sciences Legend award at bioFusion 2002. Mr. Birndorf received a B.A. in Biology from Oakland University and an M.S. in Biochemistry from Wayne State University. Mr. Birndorf received honorary Doctor of Science degrees from Oakland University and Wayne State University.

Aladar A. Szalay Ph.D.

Former Chairman & CEO of Genelux
Dr. Szalay has been the Chairman Emeritus and Chief Scientific Advisor to the CEO at Genelux Corporation since May 2014. He was Founding Director of the Center for Molecular Biology and Gene Therapy at Loma Linda University School of Medicine. He is currently a university professor at the Rudolf Virchow Center of Experimental Biomedicine, School of Medicine and at the Biocenter at the University of Würzburg in Würzburg, Germany.

James (Jim) Flatt, Ph.D.

Chief Technology Officer Synthetic Genomics Inc.
Dr. James (Jim) Flatt joined Synthetic Genomics Inc. (SGI) in 2010 as the Chief Technology Officer. SGI is a leader in the development and application of synthetic biology technology for sustainable production of fuels and chemicals and application in agriculture. Since 2013, Jim has served as President of Genovia Bio, which is responsible for the development of algal-based solutions for food fuels and chemicals markets. Jim has been involved in the industrial biotechnology field for over 20 years. Just prior to SGI, Jim was the Executive Vice President of Research & Development and Operations at Mascoma Corporation, a leader in the development of cellulosic biofuels. Prior to Mascoma. Jim served as Sr. Vice President of Research for Martek Biosciences Corporation (Columbia, MD), leading the development of nutritional fatty acids from microalgae which are now included in many infant formula and food products. Prior to Martek, Jim was involved in microbial biotechnology research at Merck and Monsanto.
Jim received his undergraduate degree in Chemical Engineering from Massachusetts Institute of Technology and graduate degrees in Chemical Engineering from the University of California-Berkeley and University of Wisconsin-Madison. Jim served as the Chairman of the Industrial Advisory Board for the National Science Foundation Engineering Research Center for Marine Biotechnology (MarBEC) at the Universities of Hawaii and California-Berkeley.